{"prompt": "['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', '9.2.3', 'Observation Period', 'Study observation period starts from subjects signing the informed consent and continues until', 'Visit 3 (Month 12). This is estimated to be about 12 months.', '9.2.4', 'Frequency of Assessments', 'Table 1 summarizes the assessments in each visit. Further details of each are given in the', 'subsequent sections.', 'This study consists of 3 visits. The study procedure and assessment contents are as follows:', 'Visit 1 (Baseline)', 'Visit 2 (Month 6)', 'Visit 3 (Month 12).', '1.', 'Visit 1 (Baseline):', 'At the initial study visit, the subject will be informed of the study objectives and overall', 'requirements, and written informed consent will be obtained prior to any study specific', 'assessments. The subject will then undergo a brief clinical evaluation to ensure compliance with', 'the inclusion and exclusion criteria to determine the eligibility (see Section 9.2.1).', 'The following data will be collected at Baseline Visit', 'Demographic details including age, gender, height and weight', 'Current medical condition and past medical history including concomitant diseases', 'MS history (including relapses within 2 years before study entry)', 'Prior MS medication', 'Prior MS medication related AEs and associated concomitant medications', 'Vital signs', 'Physical examination', 'Neurological examination', 'TSQM V II evaluation', 'MusiQoL evaluation', 'Document reasons for discontinuation of previous MS therapy', 'Therapy with Rebif', 'Date of initiation of Rebif', 'CONFIDENTIAL', '26/60', 'INFORMATION', 'M']['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', 'Initial Dose of Rebif.', 'Visit 2 (Month 6):', 'At Visit 2, the treating physician will assess the patient within standard clinical routine practice.', 'The following data will be collected at Visit 2 (Month 6):', 'Vital signs', 'Physical examination', 'Neurological examination', 'Relapse assessment', 'TSQM V II evaluation', 'MusiQoL evaluation', 'Therapy with Rebif', 'Date and dose of Rebif', 'Details of dose adjustments of Rebif if any', 'Treatment adherence', 'Safety recording and reporting according to Section 11.4 and Section 11.5', 'MS medication related AEs and associated concomitant medications', 'Visit 3 (Month 12):', 'Visit 3 (Month 12) will be similar to the above described procedure for Visit 2 (Month 6). After', 'the Month 12 visit the study ends.', 'The following data will be collected at Visit 3 (Month 12):', 'Vital signs', 'Physical examination', 'Neurological examination', 'Relapse assessment', 'TSQM V II evaluation', 'MusiQoL evaluation', 'Therapy with Rebif', 'Date and dose of Rebif', 'Details of dose adjustments of Rebif if any', 'CONFIDENTIAL', '27/60', 'INFORMATION', 'M']['Interferon beta-1a', 'MESTRE-MS Study', 'EMR200136_597', 'Treatment adherence', 'Safety recording and reporting according to Section 11.4 and Section 11.5', 'MS medication related AEs and associated concomitant medications', 'Table 1', 'Schedule of Assessments and Evaluations', 'Activity', 'Visit 1', 'Visit 2', 'Visit 3', 'Baseline', 'Month 6', 'Month 12', '(End of', 'Study', 'Visit)', 'Patient Informed Consent', 'X', 'Inclusion/Exclusion Criteria', 'X', 'Demographic information', 'X', 'Medical History / Concomitant diseases / Prior MS', 'X', 'medications', 'Multiple Sclerosis History (including relapses within 2 years', 'X', 'before study entry)', 'MS medication related adverse events and associated', 'X', 'X', 'X', 'concomitant medications', 'Vital Signs', 'X', 'X', 'X', 'Physical Examination', 'X', 'X', 'X', 'Neurological Examination', 'X', 'X', 'X', 'Relapse Assessment', 'X', 'X', 'TSQM Version Il evaluation', 'X', 'X', 'X', 'MusiQoL evaluation', 'X', 'X', 'X', 'Document reasons for discontinuation of previous MS', 'X', 'therapy', 'Therapy with Rebif', 'X', 'X', 'X', 'Evaluation of Adherence to Therapy', 'X', 'X', 'Safety Recording and Reporting', 'X', 'X', '9.2.5', 'Withdrawal from the Study', 'Subjects are free to discontinue the study at any time without giving their reasons. Subjects will', 'be withdrawn from the study for any of the following reasons:', 'Subject is lost to follow up', 'Occurrence of AE / serious adverse event (SAE), if discontinuation of Rebif is desired or', 'considered necessary by the Investigator and/or the subject', 'CONFIDENTIAL', '28/60', 'INFORMATION', 'VI']\n\n###\n\n", "completion": "END"}